New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics

Overview

Journal Expert Opin Med Diagn

Publisher Informa Healthcare

Specialties Pathology
Radiology

Date 2009 Jun 26

PMID 19554203

Citations 2

Authors

Jun S Wei

Thomas C Badgett

Javed Khan

Affiliations

Soon will be listed here.

Abstract

BACKGROUND: The completion of Human Genome Project (HGP) has paved the way for novel, more detailed and accurate molecular diagnostic classification of cancer. With the information from the HGP, cancers can be categorized not only on the morphology or limited immunohistological markers, but according to their "molecular fingerprints" such as gene expression profiles. Technologies detecting these signatures have been developed to simultaneously measure multiple genes or proteins in one assay with high sensitivity and specificity. OBJECTIVE: To evaluate potential innovative novel methods of diagnosis and prognosis in pediatric cancers. METHODS: We selected a variety of promising new diagnostic technologies utilizing molecular signatures which harness the results from HGP including DNA microarray, bead-based detection system, multiplexed RT-PCR, MesoScale Discovery (MSD), and isotope-coded affinity tag (ICAT), as well as their applications in biomarker discovery for pediatric tumors. Label-free detection technologies and the obstacles for taking these new diagnostic technologies from the bench to the bedside are also discussed. CONCLUSION: The use of molecular signatures is gaining acceptance in clinical practice. However, technical challenges need to be addressed before incorporating these new technologies into current diagnostic and prognostic schema.

Citing Articles

Treating metastatic disease: Which survival model is best suited for the clinic?.

Forsberg J, Sjoberg D, Chen Q, Vickers A, Healey J Clin Orthop Relat Res. 2012; 471(3):843-50.

PMID: 22983682 PMC: 3563791. DOI: 10.1007/s11999-012-2577-z.

Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.

Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G Oncotarget. 2011; 1(4):278-288.

PMID: 21304178 PMC: 3248110. DOI: 10.18632/oncotarget.138.

References

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Fritz J, Cooper E, Gaudet S, Sorger P, Manalis S . Electronic detection of DNA by its intrinsic molecular charge. Proc Natl Acad Sci U S A. 2002; 99(22):14142-6. PMC: 137851. DOI: 10.1073/pnas.232276699. View

Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q . Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004; 64(19):6883-91. PMC: 1298184. DOI: 10.1158/0008-5472.CAN-04-0695. View

He L, Thomson J, Hemann M, Hernando-Monge E, Mu D, Goodson S . A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-33. PMC: 4599349. DOI: 10.1038/nature03552. View

Delapeyriere O, Ollendorff V, Planche J, Ott M, Pizette S, Coulier F . Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo. Development. 1993; 118(2):601-11. DOI: 10.1242/dev.118.2.601. View

Schena M, Shalon D, Davis R, Brown P . Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270(5235):467-70. DOI: 10.1126/science.270.5235.467. View

Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A . Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005; 7(4):337-50. DOI: 10.1016/j.ccr.2005.03.019. View

Krishnan K, Khanna C, Helman L . The biology of metastases in pediatric sarcomas. Cancer J. 2005; 11(4):306-13. DOI: 10.1097/00130404-200507000-00006. View

Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J . Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286(5439):531-7. DOI: 10.1126/science.286.5439.531. View

10.

Chan J, Krichevsky A, Kosik K . MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005; 65(14):6029-33. DOI: 10.1158/0008-5472.CAN-05-0137. View

11.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

12.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

13.

Chen Q, Vansant G, Oades K, Pickering M, Wei J, Song Y . Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn. 2007; 9(1):80-8. PMC: 1867426. DOI: 10.2353/jmoldx.2007.060111. View

14.

Maris J . The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7-13. DOI: 10.1097/01.mop.0000150631.60571.89. View

15.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

16.

Calin G, Liu C, Sevignani C, Ferracin M, Felli N, Dumitru C . MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101(32):11755-60. PMC: 511048. DOI: 10.1073/pnas.0404432101. View

17.

Paweletz C, Charboneau L, Bichsel V, Simone N, Chen T, Gillespie J . Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001; 20(16):1981-9. DOI: 10.1038/sj.onc.1204265. View

18.

Khan J, Wei J, Ringner M, Saal L, Ladanyi M, Westermann F . Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001; 7(6):673-9. PMC: 1282521. DOI: 10.1038/89044. View

19.

Zhu H, Bilgin M, Snyder M . Proteomics. Annu Rev Biochem. 2003; 72:783-812. DOI: 10.1146/annurev.biochem.72.121801.161511. View

20.

Schramm A, Schulte J, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B . Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005; 24(53):7902-12. DOI: 10.1038/sj.onc.1208936. View